ArticleJournal of the American Heart Association2026
Cardioprotective Effects of Finerenone Associated With the Suppression of Myocardial Sodium Accumulation in Aldosterone/Salt-Loaded Rats.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClinical trials have indicated that finerenone, a nonsteroidal mineralocorticoid receptor antagonist, elicits considerable cardiovascular protective benefits; however, its precise mechanism of action remains to be fully elucidated.
methodsHere, we examined the impact of finerenone on myocardial injury and sodium accumulation in uninephrectomy male Sprague-Dawley rats subjected to chronic aldosterone infusion (0.75 μg/h) and salt-loading (1% NaCl) in drinking water for 4 weeks.
resultsEchocardiographic assessments and gene expression analyses revealed adverse cardiac remodeling and ventricular dysfunction with preserved ejection fraction in aldosterone/salt-loaded uninephrectomy rats. Notably, finerenone (10 mg/kg) treatment completely prevented the development of cardiac dysfunction in these animals. Additionally, sodium content in left ventricular tissues was markedly elevated in aldosterone/salt-loaded uninephrectomy rats, which was attenuated by finerenone treatment. Furthermore, a significant increase in macrophage recruitment was observed in cardiac tissues with markedly elevated M1 macrophage populations. However, finerenone treatment effectively prevented migration as well as polarization of macrophage in cardiac tissue. In an in vitro assay using RAW264.7 cells, a macrophage cell line, finerenone dramatically reduced the aldosterone/salt-induced elevation of M1 markers, whereas M2 markers exhibited a tendency to increase, potentially linked to NFAT5 (nuclear factor of activated T-cells 5)- and IL (interleukin)-10-mediated pathways.
conclusionsThese findings suggest that finerenone inhibits cardiac dysfunction induced by aldosterone/salt through the suppression of sodium accumulation in left ventricular tissues and attenuate subsequent macrophage-mediated inflammation, thereby preventing adverse cardiac remodeling and dysfunction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.